We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6-24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19-0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19-0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.

British Columbia Cancer Agency and the University of British Columbia Vancouver BC Canada

Department of Internal Medicine Haematology Charles University Hospital and Faculty of Medicine Hradec Králové Czech Republic

F Hoffmann La Roche Ltd Basel Switzerland

Georgetown University Hospital Washington DC USA

Hospital of the Ludwig Maximilians University Munich Germany

Queen Mary University of London London UK

Roche Welwyn Garden City UK

University Hospital Schleswig Holstein Kiel Germany

University of Lyon Lyon France

Washington University School of Medicine St Louis MO USA

Zobrazit více v PubMed

Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma—novel and emerging therapies. Cancer Manag Res. 2013;5:251–69. doi: 10.2147/CMAR.S34273. PubMed DOI PMC

Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856–62. doi: 10.1182/blood.V99.3.856. PubMed DOI

Hirt C, Schüler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631–40. doi: 10.1111/j.1365-2141.2008.07101.x. PubMed DOI

Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol. 2009;27:6094–100. doi: 10.1200/JCO.2009.22.6258. PubMed DOI

Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607–14. doi: 10.1200/JCO.2008.17.1561. PubMed DOI PMC

Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759–66. doi: 10.1182/blood-2013-06-507319. PubMed DOI

Lobetti-Bodoni C, Mantoan B, Monitillo L, Genuardi E, Drandi D, Barbero D, et al. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. Ther Adv Hematol. 2013;4:189–98. doi: 10.1177/2040620713480522. PubMed DOI PMC

Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398–405. doi: 10.1158/1078-0432.CCR-14-0407. PubMed DOI

Gritti G, Pavoni C, Rambaldi A. Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era? Mediterr J Hematol Infect Dis. 2017;9:e2017010. doi: 10.4084/mjhid.2017.010. PubMed DOI PMC

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–402. doi: 10.1182/blood-2009-06-225979. PubMed DOI PMC

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–42. doi: 10.1158/1535-7163.MCT-12-1182. PubMed DOI

Marcus R, Davies A, Kiyoshi A, Klapper W, Opat S, Owen C, et al. Obinutuumab for the first-line treatment of follicular lymphoma. New Engl J Med. 2017;377:1331–44. doi: 10.1056/NEJMoa1614598. PubMed DOI

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chloarambucil In patients with CLLL and coexisting conditions. N Engl J Med. 2014;370:1101–10. doi: 10.1056/NEJMoa1313984. PubMed DOI

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–93. doi: 10.1016/S1470-2045(16)30097-3. PubMed DOI

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. doi: 10.1200/JCO.2013.54.8800. PubMed DOI PMC

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36:2259–66. doi: 10.1200/JCO.2017.76.3656. PubMed DOI

van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257–317. doi: 10.1038/sj.leu.2403202. PubMed DOI

Pott C, Brüggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol. 2013;971:175–200. doi: 10.1007/978-1-62703-269-8_10. PubMed DOI

van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11. doi: 10.1038/sj.leu.2404586. PubMed DOI

Gimenez E, Chauvet M, Rabin L, Puteaud I, Duley S, Hamaidia S, et al. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang. Br J Haematol. 2012;158:186–97. doi: 10.1111/j.1365-2141.2012.09161.x. PubMed DOI

Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793–8. doi: 10.1038/sj.leu.2400801. PubMed DOI

Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, et al. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Exp Hematol. 2003;31:784–748. doi: 10.1016/S0301-472X(03)00191-7. PubMed DOI

Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126:1407–14. doi: 10.1182/blood-2015-03-630012. PubMed DOI

Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613. doi: 10.1182/blood.V128.22.613.613. PubMed DOI

Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004–13. doi: 10.1182/blood-2007-10-116749. PubMed DOI

Buchpiguel CA. Current status of PET/CT in the diagnosis and follow-up of lymphomas. Rev Bras Hematol Hemoter. 2011;33:140–7. doi: 10.5581/1516-8484.20110035. PubMed DOI PMC

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34:3758–65. doi: 10.1200/JCO.2016.67.1305. PubMed DOI

Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679–87. doi: 10.1182/blood-2015-03-635169. PubMed DOI PMC

Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, et al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica. 2016;101:e66–e68. doi: 10.3324/haematol.2015.132811. PubMed DOI PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01059630